Next Article in Journal
In Vivo Modelling of Hepatitis B Virus Subgenotype A1 Replication Using Adeno-Associated Viral Vectors
Next Article in Special Issue
miRNAs, from Evolutionary Junk to Possible Prognostic Markers and Therapeutic Targets in COVID-19
Previous Article in Journal
Immunological Mechanisms of Sickness Behavior in Viral Infection
Previous Article in Special Issue
COVID-19 Anosmia: High Prevalence, Plural Neuropathogenic Mechanisms, and Scarce Neurotropism of SARS-CoV-2?
 
 
Review

Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course

1
Department for Tropical, Travel Medicine and Immunization, Institute of Postgraduate Health Education, 100 05 Prague, Czech Republic
2
Department of Psychology, Faculty of Philosophy and Arts, Trnava University, 918 43 Trnava, Slovakia
3
Department of Pharmacology, Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic
*
Author to whom correspondence should be addressed.
Academic Editors: Seung-Beom Han and Kyung-Yil Lee
Viruses 2021, 13(11), 2246; https://doi.org/10.3390/v13112246
Received: 27 September 2021 / Revised: 29 October 2021 / Accepted: 5 November 2021 / Published: 9 November 2021
(This article belongs to the Special Issue Early Immune-Modulator Treatment in COVID-19)
Since its licensing in 1971, the synthetic compound inosine pranobex has been effectively combating viral infections, including herpes zoster, varicella, measles, and infections caused by the herpes simplex virus, human papillomavirus, Epstein–Barr virus, cytomegalovirus, and respiratory viruses. With the emergence of SARS-CoV-2, new and existing drugs have been intensively evaluated for their potential as COVID-19 medication. Due to its potent immunomodulatory properties, inosine pranobex, an orally administered drug with pleiotropic effects, can, during early treatment, alter the course of the disease. We describe the action of inosine pranobex in the body and give an overview of existing evidence collected to support further efforts to study this drug in a rigorous clinical trial setup. View Full-Text
Keywords: inosine pranobex; methisoprinol; isoprinosine; COVID-19; SARS-CoV-2; lymphopenia; immunomodulation; drug repurposing inosine pranobex; methisoprinol; isoprinosine; COVID-19; SARS-CoV-2; lymphopenia; immunomodulation; drug repurposing
Show Figures

Figure 1

MDPI and ACS Style

Beran, J.; Špajdel, M.; Slíva, J. Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course. Viruses 2021, 13, 2246. https://doi.org/10.3390/v13112246

AMA Style

Beran J, Špajdel M, Slíva J. Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course. Viruses. 2021; 13(11):2246. https://doi.org/10.3390/v13112246

Chicago/Turabian Style

Beran, Jiří, Marián Špajdel, and Jiří Slíva. 2021. "Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course" Viruses 13, no. 11: 2246. https://doi.org/10.3390/v13112246

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop